The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Osteoprotegerin, vascular calcification and atherosclerosis
Open accessAbstract
The association of bone pathologies with atherosclerosis has stimulated the search for common mediators linking the skeletal and the vascular system. Since its initial discovery as a key regulator in bone metabolism, osteoprotegerin (OPG) has become the subject of intense interest for its role in vascular disease and calcification. Studies in vitro and in animal models suggest that OPG inhibits vascular calcification. Paradoxically however, clinical studies suggest that serum OPG levels increase in association with vascular calcification, coronary artery disease, stroke and future cardiovascular events. This has led to extensive debate on the potential of OPG as a biomarker of vascular disease. However the exact significance and mechanisms by which this bone-regulatory protein influences cardiovascular pathophysiology is still unclear. The need for a more complete picture is being addressed in increasing valuable research indicating OPG as not only a marker but also a mediator of vascular pathology modulating osteogenic, inflammatory and apoptotic responses. By integrating the results of recent experimental research, animal models and clinical studies, this review summarises the present understanding of the role of OPG in vascular disease and calcification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,184
Bone morphogenetic protein expression in human atherosclerotic lesions.
Boström, K., Watson, K. E., Horn, S., Wortham, C., Herman, I. M., & Demer, L. L. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116391 · Cited by 1,020
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
Hofbauer, L. C. (2004) · JAMA · doi:10.1001/jama.292.4.490 · Cited by 988
Endothelial Function: A Critical Determinant in Atherosclerosis?
Landmesser, U., Hornig, B., & Drexler, H. (2004) · Circulation · doi:10.1161/01.cir.0000129501.88485.1f · Cited by 851
Steitz, S. A., Speer, M. Y., Curinga, G., Yang, H.-Y., Haynes, P., Aebersold, R., Schinke, T., Karsenty, G., & Giachelli, C. M. (2001) · Circulation Research · doi:10.1161/hh2401.101070 · Cited by 822
Cited by
Vascular Calcification—New Insights into Its Mechanism
Lee, S. J., Lee, I.-K., & Jeon, J.-H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082685 · Cited by 438
Vascular calcification and bone disease: the calcification paradox
Persy, V., & D’Haese, P. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.07.001 · Cited by 332
Coronary Artery Calcium Progression: An Important Clinical Measurement?
McEvoy, J. W., Blaha, M. J., DeFilippis, A. P., Budoff, M. J., Nasir, K., Blumenthal, R. S., & Jones, S. R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.038 · Cited by 255
Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis
Stojanović, S. D., Fiedler, J., Bauersachs, J., Thum, T., & Sedding, D. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz919 · Cited by 188
Garavelli, S., Bruzzaniti, S., Tagliabue, E., Di Silvestre, D., Prattichizzo, F., Mozzillo, E., Fattorusso, V., La Sala, L., Ceriello, A., Puca, A. A., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05237-x · Cited by 37
Metadata
- Authors
- Van Campenhout, A., & Golledge, J.
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 204
- Issue
- 2
- Pages
- 321-329
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W2160271093
- Cited by
- 308
- References
- 110
- FWCI
- 6.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Osteoprotegerin, vascular calcification and atherosclerosis. https://app.cochat.ai/papers/10.1016/j.atherosclerosis.2008.09.033
- The paper
- Van Campenhout, A., & Golledge, J. (2009). Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2008.09.033
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.